Arix Bioscience
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Arix Bioscience generated cash of -$4,636,000, which is more than the previous year. Cash used in financing activities reached the amount of -$63,000 last year. Net change in cash is therefore -$11,448,000.
Cash Flow
| 2017 | -8.78M | -50.24M | 105.07M |
|---|---|---|---|
| 2018 | -11.05M | -115.43M | 82.24M |
| 2019 | -8.47M | 34.13M | -986K |
| 2020 | -6.73M | 66.32M | 0 |
| 2021 | -7.13M | 42.03M | -11.59M |
| 2022 | -4.63M | -12.83M | -63K |
ARIX.L Cash Flow Statement (2017 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 134.23M | 112.08M | 54.63M | 31.00M | 74.93M | 28.92M |
Operating activities | ||||||
Net income | -27.57M | -61.08M | 126.30M | -75.56M | 42.76M | -7.69M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 229K | 209K | 335K | 446K | 503K | 506K |
Stock-based compensation expense | 181K | -266K | 25K | 2.79M | 3.33M | 3.65M |
| Deferred income tax benefit | 181K | -266K | 25K | 2.79M | 3.33M | 3.65M |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -379K | -461K | -272K | 1.06M | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 264K | -782K | 390K | -1.55M | 0 | 0 |
Cash generated by operating activities | -4.63M | -7.13M | -6.73M | -8.47M | -11.05M | -8.78M |
Investing activities | ||||||
Purchases Of Investments | -33.62M | -59.22M | -91.19M | -34.85M | 0 | 0 |
Investments In Property Plant And Equipment | -8K | -101K | -7K | -6K | -2K | -5K |
Acquisitions Net | -12.82M | -20.13M | 128.60M | -26.06M | -55.22M | -50.23M |
Cash generated by investing activities | -12.83M | 42.03M | 66.32M | 34.13M | -115.43M | -50.24M |
Financing activities | ||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 83.46M | 105.07M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -11.59M | 0 | -986K | -1.21M | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -63K | -11.59M | 0 | -986K | 82.24M | 105.07M |
Net Change In Cash | -11.44M | 22.14M | 57.44M | 23.62M | -43.92M | 46.00M |
Cash at end of period | 122.78M | 134.23M | 112.08M | 54.63M | 31.00M | 74.93M |
| Data source | Data source | Data source | Data source | Data source | Data source |